Sept. 16 Financial Quick Takes: Karyopharm, Mission Bay, Autolus, BenevolentAI, Edigene

Karyopharm in $150M royalty deal
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) entered into a royalty deal with HealthCare Royalty Partners under which it could receive up to $150 million tied to multiple myeloma drug Xpovio selinexor. Karyopharm will receive $75 million up front and is eligible for another $75 million in regulatory and commercial milestones. HCR will receive a tiered royalty in the mid-single digits based on worldwide Xpovio sales as well as any future therapies. The biotech said the deal extends its cash into mid-2021.

Mission Bay closes $60M Fund III...